|
Accession number;02A0472878
|
| Title;Applicability of antipsychotic monopharmacy and dose reduction for patients with chronic schizophrenia. |
| Author;
SUZUKI TAKEFUMI
(Keiodai I Seishinshinkeika)
WATANABE KOICHIRO
(Keiodai I Seishinshinkeika)
TAKANO HARUMASA
(Keiodai I Seishinshinkeika)
TSUNODA KEN'ICHI
(Keiodai I Seishinshinkeika)
UCHIDA HIROYUKI
(Keiodai I Seishinshinkeika)
YAGI GOHEI
(Keiodai I Seishinshinkeika)
KASHIMA HARUO
(Keiodai I Seishinshinkeika)
|
Journal Title;Annual Report of the Pharmacopsychiatry Research Foundation
|
Journal Code:Y0939A
|
ISSN:0286-7591
|
|
VOL.;NO.34;PAGE.84-92(2002)
|
| Figure&Table&Reference;TBL.5, REF.21 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Antipsychotic polypharmacy and high-dose therapy have long been used for the treatment of schizophrenia without little evidence. In order to critically evaluate their effectiveness, we I Revised usage of multiple antipsychotics(polypharmacy) to the single main agent(monopharmacy), while keeping the approximate total amount of medication II Reduced the dose of antipsychotic(s) for those receiving more than 1000mg/day. 40 chronic subjects were recruited for each study. Results from study I showed that 29(72.5%) cases were successfully maintained by monopharmacy and overall GAF score stayed unchanged. Study II indicated 35(87.5%) instances of high-dose therapy were ameliorated and GAF/CGI improved significantly. It is suggested these pharmacotherapy are overused. Antipsychotic polypharmacy is invalid for most of the cases and mere reduction of medication can be a plausible step to take. (author abst.) |
|
|
|
Related Articles;
|
